Cardiff Oncology, Inc. Common Stock
CRDFCardiff Oncology, Inc. (CRDF) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It specializes in using precision medicine approaches to identify and develop drugs that can improve outcomes for cancer patients, particularly in areas such as non-small cell lung cancer and other solid tumors.
Company News
Cardiff Oncology announced updated Phase 2 CRDF-004 data for onvansertib, a PLK1 inhibitor, will be presented at ASCO 2026 on June 2, 2026, with an investor webcast scheduled for June 3, 2026. The company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational Phase 3 trial for firs...
Cardiff Oncology announced it will present updated interim data from its Phase 2 CRDF-004 trial evaluating onvansertib, a PLK1 inhibitor, combined with standard chemotherapy and bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer at the ASCO 2026 Annual Meeting in Chicago on June 2, 2026.
Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhanced antitumor activity of trastuzumab deruxtecan and reversed resistance in therapy-resistant HER2-low breast cancer models. The findings will be presented at the AACR Annual Meeting in April 2026. Onvansertib is currently in mid-stage clinical development for...
Cardiff Oncology will participate in the Piper Sandler 37th Annual Healthcare Conference, with CEO Mark Erlander presenting on December 2, 2025, discussing their PLK1 inhibition cancer therapies and lead asset onvansertib.
The KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.
